Increasing Sophistication of Biological Drugs Driving Innovations in Needle-Free Drug Delivery

Complex new therapeutics and biological drugs are rendering traditional delivery methods obsolete. Innovations in needle-free drug delivery are being driven by the increasing sophistication of biological drugs.

Hartford, CT, September 08, 2011 --( Global Information Inc. presents a new market research report, “Needle-Free Drug Delivery: The Market for Alternatives to Needle-Based Systems for Vaccine and Biologics” by Kalorama Information. (For more details:

Kalorama estimates that needle-free drug delivery methods--which include patches, edible vaccines, pen injectors and more--will likely see a significant increase in revenues, with annual growth averaging 15.1% from 2011 through 2016 to reach $6.2 billion.

Drug delivery technology has evolved rapidly in the last 25 years. Initially seen as merely a medium for a drug, it is now viewed as a tool for modifying the pharmacologic properties of drugs, improving methods of delivery, and targeting drugs to specific locations. Progress in the fields of microencapulation, polymer technology and nanoparticles now allow scientists to prolong the effect of drugs with short half-lives. Companies are developing a new generation of delivery systems for increasingly sophisticated biological drugs.

Arizona Biodesign Institute in Tempe is in the vanguard of the movement toward edible vaccines. The institute has concluded three early-stage clinical trials using potatoes bearing vaccines against hepatitis B, E. coli and the Norwalk Virus. Similarly, researchers at Japan's National Institute of Agrobiological Sciences continue to develop an edible vaccine produced in genetically modified rice.

"The line between drug delivery and drug substance will become increasingly elusive in the near future, as researchers work to improve drug properties through drug design and molecular modeling," notes Bruce Carlson, Kalorama Information's publisher. "In the next decade, drug delivery technologies will be a focal point of competition and the success of specific drugs will be tied to innovative delivery techniques, which will enable the targeting that will exploit the clinical properties of a new generation of drugs."

Competition in the segment has spiked over the past decade; top delivery technology companies Antares, Bioject, MediImmune and Zogenix compete for market share. Bioject offers several proprietary delivery technologies, including Biojector 2000,, Injex, Serojet, and Vitajet, which are used in a wide range of applications including insulin, vaccine, and hormone drug delivery. Zogenix offers the Intraject system, which is a pre-filled, disposable, needle-free injector for the delivery of a wide range of liquid drugs, therapeutic proteins, and vaccines.

The new report examines drug delivery technologies within the pharmaceutical marketplace. It provides a comprehensive market overview, product descriptions, market estimates and forecasts, company profiles, delivery technology industry trends, and more.

Browse their collection of Drug Delivery System Market Research Reports:

About Global Information Inc.
Global Information (GII) ( is an information service company partnering with over 300 research companies around the world. Global Information has been in the business of distributing technical and market research for more than 25 years. Expanded from its original headquarters in Japan, Global Information now has offices in Korea, Taiwan, Singapore, Europe and the United States.

Jeremy Palaia
Global Information, Inc.
195 Farmington Avenue
Suite 208, Farmington, CT 06032 USA
Toll Free (US & Canada): +1-866-353-3335
Outside US: +1-860-674-8796

Global Information Inc.
Yuko Ueki